Cohance Lifesciences Ltd
Cohance Lifesciences Ltd Share Price Today: Live Updates & Key Insights
Get insights on Cohance Lifesciences Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Cohance Lifesciences Ltd Share Price Chart
Cohance Lifesciences Ltd Fundamentals
Traded Volume: 7,55,946
Market Cap(Cr): 22,545
Avg Traded Price 590.15
1 Year return -53.76%
Upper Circuit 601.9
Lower Circuit 576.1
P/E TTM 91.00
P/B Ratio 6.00
Traded Value(Cr) 4454.79
EPS TTM 6.479
Book value 6.479
Dividend 0.00%
Cohance Lifesciences Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Cohance Lifesciences Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Cohance Lifesciences Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -6.33%
1M -32.91%
3M -34.14%
1Y -53.76%
YTD -48.16%
Cohance Lifesciences Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Cohance Lifesciences Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 4.66L
Day Before Yesterday 16.93L
1W Avg 12.37L
1M Avg 12.87L
3M Avg 15.16L
Cohance Lifesciences Ltd Technical Details
Cohance Lifesciences Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 576
Support 2 563
Support 3 551
Pivot Point : 589
Resistance 1 602
Resistance 2 615
Resistance 3 628
Cohance Lifesciences Ltd Corporate Actions
Cohance Lifesciences Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Cohance Lifesciences Ltd’s capital allocation strategies.
All
Ex-Date 09-Sep-2022 Type D Description 1.00/share@100.00% Record Date 12-Sep-2022 Ratio 100.00
Ex-Date 09-Sep-2022 Type D Description 5.00/share@500.00% Record Date 12-Sep-2022 Ratio 500.00
Ex-Date 13-May-2022 Type D Description 1.00/share@100.00% Record Date 17-May-2022 Ratio 100.00
Ex-Date 13-May-2022 Type D Description 1.00/share@100.00% Record Date 17-May-2022 Ratio 100.00
Ex-Date 15-Feb-2022 Type D Description 2.00/share@200.00% Record Date 16-Feb-2022 Ratio 200.00
Ex-Date 15-Feb-2022 Type D Description 1.00/share@100.00% Record Date 16-Feb-2022 Ratio 100.00
Ex-Date 13-Aug-2021 Type D Description 1.00/share@100.00% Record Date 17-Aug-2021 Ratio 100.00
Ex-Date 17-Feb-2021 Type D Description 1.00/share@100.00% Record Date 18-Feb-2021 Ratio 100.00
Ex-Date 25-Sep-2020 Type B Description share@1:1 Record Date 28-Sep-2020 Ratio 1:1
Dividends
Announcement Date 09-Sep-2022 Ex Dividend Date 09-Sep-2022 Dividend(%) 100
Announcement Date 09-Sep-2022 Ex Dividend Date 09-Sep-2022 Dividend(%) 500
Announcement Date 13-May-2022 Ex Dividend Date 13-May-2022 Dividend(%) 100
Announcement Date 13-May-2022 Ex Dividend Date 13-May-2022 Dividend(%) 100
Announcement Date 15-Feb-2022 Ex Dividend Date 15-Feb-2022 Dividend(%) 100
Announcement Date 15-Feb-2022 Ex Dividend Date 15-Feb-2022 Dividend(%) 200
Announcement Date 13-Aug-2021 Ex Dividend Date 13-Aug-2021 Dividend(%) 100
Announcement Date 17-Feb-2021 Ex Dividend Date 17-Feb-2021 Dividend(%) 100
Bonus
Record Date 28-Sep-2020 Ex-Bonus Date 25-Sep-2020 Ratio 1:1
Splits
No Split has been declared by COHANCE
Others
Rights No Rights has been declared by COHANCE
Cohance Lifesciences Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Cohance Lifesciences Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Cohance Lifesciences Ltd's relative performance and valuation against major competitors.
Stock Name Piramal Pharma Ltd ₹188.38 (-0.66%) M. Cap (Cr) 250.40 1 Yr Return (%) -23.39% P/E (TTM) -1054.76 PB Ratio 3.16
Stock Name Pfizer Ltd ₹5000.50 (-0.56%) M. Cap (Cr) 228.76 1 Yr Return (%) -2.55% P/E (TTM) 27.26 PB Ratio 5.42
Stock Name ERIS Lifesciences Ltd ₹1666.00 (-0.22%) M. Cap (Cr) 226.94 1 Yr Return (%) +21.88% P/E (TTM) 54.60 PB Ratio 8.19
Stock Name Cohance Lifesciences Ltd ₹589.30 (+1.28%) M. Cap (Cr) 225.45 1 Yr Return (%) -53.76% P/E (TTM) 90.96 PB Ratio 13.19
Stock Name Astrazeneca Pharma India Ltd ₹8988.00 (-1.59%) M. Cap (Cr) 224.70 1 Yr Return (%) +42.54% P/E (TTM) 112.83 PB Ratio 33.08
Stock Name Wockhardt Ltd ₹1311.30 (-1.04%) M. Cap (Cr) 213.08 1 Yr Return (%) +11.63% P/E (TTM) -926.42 PB Ratio 6.27
Stock Name Neuland Laboratories Ltd ₹16598.00 (-0.72%) M. Cap (Cr) 212.95 1 Yr Return (%) +12.39% P/E (TTM) 88.68 PB Ratio 15.26
Cohance Lifesciences Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Cohance Lifesciences Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 301.03 Mar 2024 370.65 Mar 2023 484.17 Mar 2022 269.89 Mar 2021 329.73
PARTICULARS Investing Activities Mar 2025 -320.94 Mar 2024 -381.58 Mar 2023 -235.57 Mar 2022 -90.36 Mar 2021 -257.66
PARTICULARS Financing Activities Mar 2025 20.81 Mar 2024 -13.78 Mar 2023 -235.79 Mar 2022 -156.41 Mar 2021 -76.55
PARTICULARS Net Cash Flow Mar 2025 0.90 Mar 2024 -24.71 Mar 2023 12.81 Mar 2022 23.12 Mar 2021 -4.48
Cohance Lifesciences Ltd Shareholding Pattern
This shows the ownership breakdown of Cohance Lifesciences Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 57.49%
Public 15.16%
Other Institutions 4.33%
FII 6.51%
Mutual Funds 16.49%
About Cohance Lifesciences Ltd
Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018. The name of the Company has been changed to Cohance Lifesciences Limited w.e.f. May 7, 2025. Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors. The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS Business Undertaking Division to the Company through the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company. In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020.The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each.The company has a massive Rs 320-crore capex plan. Suven has invested Rs 120 crore in 2019-20. The balance is to be invested in 2020-21.During the year 2019-20, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 2019-2020.As on 31 March 2020,the company has one subsidiary and one associate company under its roof.The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator.The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956..In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022.During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.The Company acquired 67.5% stake in Sapala Organics Private Limited, making it a subsidiary of the Company w.e.f. July 12, 2024. The Company acquired 56% equity share capital of NJ Bio, Inc., making it a subsidiary effective from December 20, 2024. The wholly owned subsidiary, Casper Pharma Private Limited was merged into the Company and the Scheme of Amalgamation became effective from January 1, 2025. Similarly, Cohance Lifesciences Limited has merged with and into Suven Pharmaceuticals Limited w.e.f May 1, 2025.
Non Executive Director
Shweta Jalan
Registered office 8-2-334 SDE Serene Chambers, 3 Floor Avenue 7 Road No 5, Hyderabad, Telangana, 500034
FAX :91-40-23549414/1142/3311
Background
Incorporation Year 2018
Face Value ₹1.00
Market Lot 1
FAQs on Cohance Lifesciences Ltd
How to buy Cohance Lifesciences Ltd shares on NSE?
To buy Cohance Lifesciences Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Cohance Lifesciences Ltd share price today?
The Cohance Lifesciences Ltd share price on NSE is ₹589.30 today.
What is the market cap of Cohance Lifesciences Ltd on NSE?
The company has a market capitalization of ₹22544.68.
What is the PE & PB ratio of Cohance Lifesciences Ltd?
PE is 91 and PB is 6.
What is the 52 Week High and Low of Cohance Lifesciences Ltd shares?
Cohance Lifesciences Ltd stock price high: ₹1360 Cohance Lifesciences Ltd stock price low: ₹573.80.